New pharmaceutical compositions for treatment of thrombosis
AssigneeBoehringer Ingelheim International GmbH
InventorsPaul Reilly, James Gilbert, Thomas Mueller
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel pharmaceutical compositions comprising at least one direct thrombin inhibitor and at least one additional active compound selected from the groups consisting of platelet inhibitors, low molecular weight heparins (LMWH) and heparinoids as well as unfractionated heparin, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, fibrinogen receptor antagonists (glycolprotein IIb/IIa antagonists) and Vitamin K antagonists, optionally together with one or more pharmaceutically acceptable excipients or carriers for the treatment of thrombosis.
Claims27
A pharmaceutical composition comprising at least one direct thrombin inhibitor 1 selected from the group consisting of:
- (1.1) ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate (dabigatran),
- (1.2) 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide,
- (1.3) 1-methyl-2-[4-(N-hydroxyamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-ethoxycarbonylethyl)-amide
- (1.4) melagatran (inogatran),
- (1.5) ximelagatran,
- (1.6) hirudin,
- (1.7) hirolog and
- (1.8) argatroban,
- optionally in the form of tautomers, racemates, enantiomers, diastereomers, pharmacologically acceptable acid addition salts, solvates or hydrates, prodrugs thereof,
- and one or more active compounds 2 selected from the group consisting of:
- platelet inhibitors 2a, low molecular weight heparins (LMWH) and heparinoids as well as unfractionated heparin 2b, factor Xa inhibitors 2c, combined thrombin/factor Xa inhibitors 2d, fibrinogen receptor antagonists (glycoprotein IIb/IIa antagonists) 2e and Vitamin K antagonists 2f, optionally together with one or more pharmaceutically acceptable excipients or carriers.
Dependencies are inferred from the claim text.